VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality.
Volition reported that most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. According to the press release, the full details are available at https://ibn.fm/2IH3m.
Sepsis remains a leading cause of death worldwide, and early diagnosis is critical for improving outcomes. Current diagnostic methods often rely on clinical assessment and laboratory tests that may lack specificity. The Nu.Q NETs assay, which detects nucleosomes released during NETosis, offers a potential non-invasive tool for early detection and monitoring of sepsis. The growing evidence suggests that this test could be integrated into clinical practice to help clinicians make more informed decisions about treatment.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The implications of this announcement are significant. If the Nu.Q NETs test gains wider clinical acceptance, it could transform sepsis management by enabling earlier intervention and more personalized treatment strategies. This could reduce mortality rates and healthcare costs associated with sepsis. Moreover, the technology's application in other NETosis-related diseases could broaden its impact.
For further information about Volition and its technology, visit the company’s website at https://volition.com/.
